No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Gene Huang and Vance Moore Appointed to the Caregility Advisory Board: Together They Bring to the Table Over 35+ Years of Executive Industry Experience

Editor: What To Know

  • He is an active investor in healthcare ventures and a graduate of Cornell University with a Masters in the Management of Technology from MIT.
  • He is on the governing committee of the National Evaluation System for health Technology (NESTcc) and is a board member of Omnicell Incorporated, L.
  • From critical and acute, to urgent and emergent, to post-acute and ambulatory, and to the home, Caregility is helping transform the delivery of patient care everywhere.

January 6, 2021

Gene Huang, Vance Moore

Gene Huang and Vance Moore are the latest appointments to the Caregility advisory board.

Gene Huang and Vance Moore will bring operational guidance to Caregility’s efforts to support healthcare’s Quadruple Aim by enabling the fastest path to care with the right caregiver and treatment plan.

Gene Huang brings over 30 years of experience building healthcare businesses – including health services companies, health plans, provider organizations, and, most recently, payment reform and value-based care initiatives in the post-acute setting for skilled nursing facilities – to the new role with Caregility. He currently serves as CEO of CapZone Healthcare, a venture focused on curating healthcare investment opportunities in low-income Opportunity Zones.

Prior to that, Gene Huang led a multi-state physician home visit company that was sold to CIGNA, built and managed the Medicare Advantage business for multiple health plans, built Chronic Special Needs Plans for Aveta, and ran the nationwide 24-hour nurse line for IntraCorp/CIGNA HealthCare. Over the last six years, Huang led the post-acute business for Remedy Partners, the largest player in the CMS Bundled Payment for Care Improvement program. He is an active investor in healthcare ventures and a graduate of Cornell University with a Masters in the Management of Technology from MIT.

Vance Moore brings over 35 years of experience in healthcare operations and supply chain management to the new role with Caregility. He currently serves as the founder of RocketStop, a healthcare advisory services firm that specializes in helping organizations optimize customer impact and market potential. He recently retired from Mercy where he served over 18 years leading innovation and development of Mercy’s supply chain, technology, and decision science divisions, most recently serving as president of business integration for Mercy Virtual.

Prior to Mercy, Vance Moore garnered 17 years of experience in healthcare with Baxter/Allegiance/Cardinal Health and the healthcare division of the UPS Logistics Group. He is on the governing committee of the National Evaluation System for health Technology (NESTcc) and is a board member of Omnicell Incorporated, L.E.K Consulting’s life science and med-tech expert network, and Mission:318. He was recognized as SCM World’s 2015 “visionary of the year” and was inducted into the healthcare supply chain hall of fame in 2019.

“Gene Huang and Vance Moore bring a wealth of knowledge and experience to Caregility’s advisory board,” said Ron Gaboury, CEO of Caregility. “Gene’s extensive expertise launching successful value-based care initiatives across a broad spectrum of health sectors and Vance’s depth of expertise in the healthcare supply chain and virtual process engineering will be invaluable assets in Caregility’s growth strategy. We’re honored to welcome them both to the team.”

“I recognize the pivotal role that reliable, innovative technologies play in helping healthcare achieve the Quadruple Aim,” said Huang. “Caregility’s virtual care solutions are changing the point of care at a time when healthcare needs it the most. I share their mission to improve patient access and health equity and look forward to sharing my experience and working with the team.”

“Our collective mission to drive out unproductive variation in care mirrors Caregility’s unwavering focus on improving patient and staff experiences to support the best possible patient outcomes,” said Moore. “I look forward to working with the team to identify new, innovative ways we can bring greater efficiency to care delivery.”

 Caregility is a clinical collaboration and communications company moving the access point of care closer to the patient. Leveraging over eight years of experience in clinical environments, the Caregility telehealth platform is a purpose-built ecosystem for the entire healthcare continuum. The platform provides secure, reliable two-way audio and video communication designed for any device and clinical workflow, in both inpatient and outpatient settings. Today, Caregility supports more than 2 million video sessions annually and has deployed over 9,000 access points of care systems across the US. From critical and acute, to urgent and emergent, to post-acute and ambulatory, and to the home, Caregility is helping transform the delivery of patient care everywhere.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy